You are here: Home » Companies » News
Business Standard

USFDA completes Chennai facility audit with zero observations: Natco Pharma

Shares of Natco Pharma were trading 0.35 per cent higher at Rs 529.95 apiece on BSE

Press Trust of India  |  New Delhi 

Indians and Chinese supply 80 per cent of active ingredients to the US  and Indians alone are responsible for  40-45 per cent of finished dosages

on Monday said the US health regulator has completed the inspection of its Chennai facility, and it ended with zero observations.

In a regulatory filing, announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Chennai, India, conducted during the period July 8-12, 2019".

"The regulatory audit resulted in zero observations," the company added.

Shares of were trading 0.35 per cent higher at Rs 529.95 apiece on BSE.

First Published: Mon, July 15 2019. 10:50 IST
RECOMMENDED FOR YOU